Kimberly-Clark: A Dividend King with a Steady Demand for Its Products Despite Tariff Troubles
ByAinvest
Sunday, Apr 27, 2025 6:02 pm ET1min read
KMB--
Kimberly-Clark's international tissue business, valued at approximately $4 billion, is in the final stages of negotiation with three major industry players—Royal Golden Eagle, Asia Pulp & Paper, and Suzano (SUZ)—preparing to submit their definitive offers by mid-May. The sale is anticipated to significantly impact the global tissue market and provide Kimberly-Clark with substantial resources to focus on its core markets and strategic priorities [1].
Analysts forecast an average target price of $144.17 for Kimberly-Clark, with a high estimate of $162.00 and a low estimate of $118.00. The consensus brokerage recommendation is a "Hold" status, indicating cautious optimism among investors [1]. Despite these forecasts, Kimberly-Clark continues to face external challenges, including a softer-than-expected top line in the first quarter and a $300 million impact from tariffs [1].
American advisors and investors are increasingly turning to Asian consumer stocks, which have shown resilience amidst broader market turmoil. This shift is driven by expectations that consumer staples companies in large Asian markets are more resilient to market headwinds and will benefit from swift economic stimulus [2].
Kimberly-Clark's ability to maintain its dividend streak in the face of these challenges underscores its financial stability and commitment to shareholder value. For investors seeking a reliable dividend stock, Kimberly-Clark offers a compelling opportunity despite the current market volatility.
References:
[1] https://www.gurufocus.com/news/2800179/kimberlyclark-kmb-attracts-final-bids-for-4-billion-tissue-business-kmb-stock-news
[2] https://stocktwits.com/news-articles/markets/equity/asian-consumer-stocks-emerge-as-safe-bets/chQi4jgRbQb
Kimberly-Clark, a consumer staples giant, reported weaker-than-expected results and cut its full-year outlook due to pressures from tariffs. Despite this, the company has raised its dividend for 53 consecutive years, earning it a spot on the list of Dividend Kings. With a 3.8% yield, Kimberly-Clark is a reliable dividend stock to buy now for risk-averse investors.
Kimberly-Clark (KMB) has faced challenges in its recent financial performance, with weaker-than-expected results and a full-year outlook cut due to tariff pressures. Despite these headwinds, the company has maintained its impressive streak of raising its dividend for 53 consecutive years, solidifying its status as a Dividend King. With a current yield of 3.8%, Kimberly-Clark remains an attractive option for risk-averse investors seeking stable income.Kimberly-Clark's international tissue business, valued at approximately $4 billion, is in the final stages of negotiation with three major industry players—Royal Golden Eagle, Asia Pulp & Paper, and Suzano (SUZ)—preparing to submit their definitive offers by mid-May. The sale is anticipated to significantly impact the global tissue market and provide Kimberly-Clark with substantial resources to focus on its core markets and strategic priorities [1].
Analysts forecast an average target price of $144.17 for Kimberly-Clark, with a high estimate of $162.00 and a low estimate of $118.00. The consensus brokerage recommendation is a "Hold" status, indicating cautious optimism among investors [1]. Despite these forecasts, Kimberly-Clark continues to face external challenges, including a softer-than-expected top line in the first quarter and a $300 million impact from tariffs [1].
American advisors and investors are increasingly turning to Asian consumer stocks, which have shown resilience amidst broader market turmoil. This shift is driven by expectations that consumer staples companies in large Asian markets are more resilient to market headwinds and will benefit from swift economic stimulus [2].
Kimberly-Clark's ability to maintain its dividend streak in the face of these challenges underscores its financial stability and commitment to shareholder value. For investors seeking a reliable dividend stock, Kimberly-Clark offers a compelling opportunity despite the current market volatility.
References:
[1] https://www.gurufocus.com/news/2800179/kimberlyclark-kmb-attracts-final-bids-for-4-billion-tissue-business-kmb-stock-news
[2] https://stocktwits.com/news-articles/markets/equity/asian-consumer-stocks-emerge-as-safe-bets/chQi4jgRbQb

Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue

Comments
No comments yet